Guggenheim Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $50
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Vamil Divan has initiated coverage on Insmed (NASDAQ:INSM) with a Buy rating and a price target of $50.
July 26, 2023 | 9:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim has initiated coverage on Insmed with a Buy rating and a price target of $50, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Guggenheim's Buy rating and $50 price target for Insmed suggest a positive outlook for the stock, which could attract more investors and drive up its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100